Biotronik/Aachen Lekton Vita DES Slated For Q4 2004 European Launch
This article was originally published in The Gray Sheet
Executive Summary
Aachen Resonance will begin a randomized trial of its Tretinoin compound on Biotronik's Lekton Motion stent system early next year under a Nov. 19 pact giving Biotronik commercialization rights
You may also be interested in...
Conor Medsystems, Biotronik DES Would Compete With Established Players
Conor Medsystems expects technological characteristics - not price - will successfully position its CoStar drug-eluting stent against offerings from Johnson & Johnson and Boston Scientific
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.